Literature DB >> 12732872

Immunopathology and the gene therapy of lupus.

R A Mageed1, G J Prud'homme.   

Abstract

Lupus is a chronic autoimmune inflammatory disease with complex clinical manifestations. In humans, lupus, also known as systemic lupus erythematosus (SLE), affects between 40 and 250 individuals, mostly females, in each 100 000 of the population. There are also a number of murine models of lupus widely used in studies of the genetics, immunopathology, and treatment of lupus. Human patients and murine models of lupus manifest a wide range of immunological abnormalities. The most pervasive of these are: (1) the ability to produce pathogenic autoantibodies; (2) lack of T- and B-lymphocyte regulation; and (3) defective clearance of autoantigens and immune complexes. This article briefly reviews immunological abnormalities and disease mechanisms characteristic of lupus autoimmunity and highlight recent studies on the use of gene therapy to target these abnormalities.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12732872     DOI: 10.1038/sj.gt.3302016

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  13 in total

1.  Association of IL-10 level and IL-10 promoter SNPs with specific antibodies in penicillin-allergic patients.

Authors:  Hai-Ling Qiao; Qiang Wen; Na Gao; Xin Tian; Lin-Jing Jia
Journal:  Eur J Clin Pharmacol       Date:  2007-01-16       Impact factor: 2.953

2.  CD5+ B lymphocytes in systemic lupus erythematosus patients: relation to disease activity.

Authors:  Hanan Hassan Omar; Samah Ismail Nasef; Hamdy Hassan Omar; Mona Sayed Ghaly
Journal:  Clin Rheumatol       Date:  2017-09-16       Impact factor: 2.980

Review 3.  Connective tissue disorders and cardiovascular complications: the indomitable role of transforming growth factor-beta signaling.

Authors:  Jason B Wheeler; John S Ikonomidis; Jeffrey A Jones
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

Review 4.  The problem of accelerated atherosclerosis in systemic lupus erythematosus: insights into a complex co-morbidity.

Authors:  N S Wade; A S Major
Journal:  Thromb Haemost       Date:  2011-10-06       Impact factor: 5.249

5.  Connective Tissue Disorders and Cardiovascular Complications: The Indomitable Role of Transforming Growth Factor-β Signaling.

Authors:  Jason B Wheeler; John S Ikonomidis; Jeffrey A Jones
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  Repopulation of B-lymphocytes with restricted gene expression using haematopoietic stem cells engineered with lentiviral vectors.

Authors:  T E Taher; C Tulone; R Fatah; F D'Acquisto; D J Gould; R A Mageed
Journal:  Gene Ther       Date:  2008-03-20       Impact factor: 5.250

7.  Loss of LFA-1, but not Mac-1, protects MRL/MpJ-Fas(lpr) mice from autoimmune disease.

Authors:  Christopher G Kevil; M John Hicks; Xiaodong He; Junxuan Zhang; Christie M Ballantyne; Chander Raman; Trenton R Schoeb; Daniel C Bullard
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

8.  Expression of TGFbeta1 and its signaling components by peripheral lymphocytes in systemic lupus erythematosus.

Authors:  Eszter Kohut; Melinda Hajdu; Péter Gergely; László Gopcsa; Katalin Kilián; Katalin Pálóczi; László Kopper; Anna Sebestyén
Journal:  Pathol Oncol Res       Date:  2008-11-20       Impact factor: 3.201

Review 9.  Autoimmune mechanisms in children with systemic lupus erythematosus.

Authors:  Dorothee Stichweh; Virginia Pascual
Journal:  Curr Rheumatol Rep       Date:  2005-12       Impact factor: 4.686

10.  Prevalence of ZAP-70, LAT, SLP-76, and DNA methyltransferase 1 expression in CD4+ T cells of patients with systemic lupus erythematosus.

Authors:  Radosław Januchowski; Mariusz Wudarski; Hanna Chwalińska-Sadowska; Paweł P Jagodzinski
Journal:  Clin Rheumatol       Date:  2007-05-11       Impact factor: 3.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.